Mesoblast Limited [NASDAQ: MESO] stock went on a downward path that fall over -1.12% on Friday, amounting to a one-week price increase of more than 12.24%. The company report on January 12, 2021 that Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblast’s presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at https://journey.ct.events/view/f353f7fd-772e-43aa-aab0-e959da38254d. An archived webcast of the conference presentation will be available for 90 days on the Company’s website at www.mesoblast.com.
The randomized controlled Phase 3 trial compared clinical outcomes between rexlemestrocel-L and sham control in 537 treated patients with chronic heart failure and reduced left ventricular ejection fraction (HFrEF).
Over the last 12 months, MESO stock rose by 25.42%. The one-year Mesoblast Limited stock forecast points to a potential upside of 35.03. The average equity rating for MESO stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.14 billion, with 116.50 million shares outstanding and 115.83 million shares in the current float. Compared to the average trading volume of 807.85K shares, MESO stock reached a trading volume of 901403 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Mesoblast Limited [MESO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MESO shares is $14.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MESO stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Mesoblast Limited shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 22, 2020. The new note on the price target was released on December 04, 2020, representing the official price target for Mesoblast Limited stock. Previously, the target price had yet another raise to $12, while RBC Capital Mkts analysts kept a Sector Perform rating on MESO stock. On August 14, 2020, analysts increased their price target for MESO shares from 16 to 22.
The Average True Range (ATR) for Mesoblast Limited is set at 1.05, with the Price to Sales ratio for MESO stock in the period of the last 12 months amounting to 69.81. The Price to Book ratio for the last quarter was 2.10, with the Price to Cash per share for the same quarter was set at 0.92.
MESO Stock Performance Analysis:
Mesoblast Limited [MESO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.24. With this latest performance, MESO shares dropped by -42.69% in over the last four-week period, additionally sinking by -17.35% over the last 6 months – not to mention a rise of 25.42% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MESO stock in for the last two-week period is set at 43.59, with the RSI for the last a single of trading hit 45.91, and the three-weeks RSI is set at 43.19 for Mesoblast Limited [MESO]. The present Moving Average for the last 50 days of trading for this stock 12.08, while it was recorded at 10.27 for the last single week of trading, and 12.53 for the last 200 days.
Insight into Mesoblast Limited Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Mesoblast Limited [MESO] shares currently have an operating margin of -238.79 and a Gross Margin at +19.94. Mesoblast Limited’s Net Margin is presently recorded at -246.54.
Return on Total Capital for MESO is now -12.92, given the latest momentum, and Return on Invested Capital for the company is -13.91. Return on Equity for this stock declined to -15.68, with Return on Assets sitting at -10.56. When it comes to the capital structure of this company, Mesoblast Limited [MESO] has a Total Debt to Total Equity ratio set at 18.08. Additionally, MESO Total Debt to Total Capital is recorded at 15.31, with Total Debt to Total Assets ending up at 12.22. Long-Term Debt to Equity for the company is recorded at 11.53, with the Long-Term Debt to Total Capital now at 9.77.
Reflecting on the efficiency of the workforce at the company, Mesoblast Limited [MESO] managed to generate an average of -$1,139,840 per employee. Receivables Turnover for the company is 11.69 with a Total Asset Turnover recorded at a value of 0.04.Mesoblast Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
MESO Stock EPS
With the latest financial reports released by the company, Mesoblast Limited posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 75.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MESO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mesoblast Limited go to 48.80%.
Mesoblast Limited [MESO] Insider Position Details
Positions in Mesoblast Limited stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 37 institutional holders increased their position in Mesoblast Limited [NASDAQ:MESO] by around 1,369,835 shares. Additionally, 15 investors decreased positions by around 945,611 shares, while 8 investors held positions by with 973,920 shares. The mentioned changes placed institutional holdings at 3,289,366 shares, according to the latest SEC report filing. MESO stock had 17 new institutional investments in for a total of 635,322 shares, while 8 institutional investors sold positions of 164,362 shares during the same period.